Investment case
Cue Biopharma, Inc.
CUE · 2 developments mapped · last assessed 2026-09-21
Market Ontology has mapped 2 macro, policy, and market developments to Cue Biopharma, Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for CUE yet, so no modelled value is shown. The CUE valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run CUE on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study
Direct clinical trial success, increasing probability of regulatory approval and commercialization. Reduces R&D risk.
· Moves probability of success (pos) for cue 221, peak sales estimates for cue 221, discount rate (risk premium)
- Open question
Cue Biopharma, Inc. Follow-On — $50M
Dilution of existing shareholders, but also strengthened balance sheet and extended cash runway for R&D.
· Moves equity value per share, cash burn rate, probability of success clinical trials
What changed, by assumption
- 2026-09-21Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study
- 2026-08-14Cue Biopharma, Inc. Follow-On — $50M
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-09-21 | Revenue | Bullish | Positive Phase 2 data for CUE-221 increases the probability of technical success and future commercialization in CSU and food allergy markets. | 0.85 |
| 2026-08-15 | Net debt | Bearish | Completion of a $50 million private placement financing increases cash position. | 0.90 |
| 2026-08-15 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-15 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-21 | Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study | Bullish | 1-3m | 0.90 |
| 2026-08-14 | Cue Biopharma, Inc. Follow-On — $50M | mixed | 1-3m | 0.70 |